Dense array EEG outperforms other typically available noninvasive modalities in predicting positive surgical outcomes for patients with drug-resistant epilepsy.
Improving neurological health is one of the key challenges of the twenty-first century. Electrical Geodesics Incorporated (EGI) has developed a dense array electroencephalography (dEEG) technology that is now widely used in human neuroscience research laboratories around the world, addressing topics such as the mechanisms of visual attention, the abnormal frontal lobe development in autism, and the neurophysiological processes of normal sleep.
To bring this research technology to clinical practice, EGI introduced clinical dEEG systems for long-term monitoring for epilepsy evaluation. As with other applications of neurological assessment, the result is improved guidance of therapy (in this case, neurosurgical intervention). With the accuracy of 128- and 256-channel recordings, the dEEG analysis can be registered precisely with magnetic resonance images to align brain function with brain anatomy. Because the Geodesic EEG System is comfortable and easy to apply, new markets are developing for which patient acceptance and efficiency of clinical protocol are primary considerations, such as routine clinical EEG and sleep medicine.
